| __timestamp | Amneal Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 24419536 |
| Thursday, January 1, 2015 | 109679000 | 34718089 |
| Friday, January 1, 2016 | 118757000 | 40998209 |
| Sunday, January 1, 2017 | 109046000 | 32022880 |
| Monday, January 1, 2018 | 230435000 | 19110051 |
| Tuesday, January 1, 2019 | 289598000 | 26556257 |
| Wednesday, January 1, 2020 | 326727000 | 52275890 |
| Friday, January 1, 2021 | 365504000 | 80981000 |
| Saturday, January 1, 2022 | 399700000 | 124431000 |
| Sunday, January 1, 2023 | 429675000 | 90932000 |
| Monday, January 1, 2024 | 98761000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry players is crucial. Amneal Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, peaking at approximately $430 million in 2023. This reflects a strategic investment in scaling operations and market presence. In contrast, Arrowhead's SG&A expenses grew more modestly, increasing by around 270% to nearly $91 million in 2023. This suggests a more conservative approach, possibly focusing on niche markets or innovative R&D. Notably, data for 2024 is incomplete, highlighting the dynamic nature of financial planning in this sector. These trends underscore the diverse strategies companies employ to navigate the ever-evolving pharmaceutical landscape.
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Zoetis Inc. vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Blueprint Medicines Corporation or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Amneal Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE